Press Releases

Wacker Chemie AG saw its sales decline in the third quarter of 2024 due to the ongoing difficult market environment.

Wacker Chemie AG is using today’s Capital Markets Day as an opportunity to confirm the growth and sustainable development goals communicated in 2022.

MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS) and Wacker Biotech, a contract development and manufacturing organization (CDMO), wholly owned subsidiary of Wacker Chemie AG, today announce a collaboration to manufacture MinervaX’s active protein ingredients of its GBS vaccine.

WACKER has successfully captured carbon dioxide (CO₂) generated from silicon production.

WACKER is expanding its specialty portfolio for the semiconductor industry with the development of a new precursor silane for the fabrication of highly integrated memory chips and microprocessors.